Cited by 853Health Systems, Economic Evaluations, Quality of LifePharmaceutical Economics and PolicyGlobal Health Care Issues

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Thresholds for the cost–effectiveness of interventions: alternative approaches

Open access

Marseille, Elliot, Larson, Bruce, Kazi, Dhruv S, Kahn, James G, Rosen, Sydney·2015·Bulletin of the World Health Organization

DOI 10.2471/blt.14.138206PMC PMC4339959

Open this paper in CoChat — free account

Abstract

Many countries use the cost-effectiveness thresholds recommended by the World Health Organization's Choosing Interventions that are Cost-Effective project (WHO-CHOICE) when evaluating health interventions. This project sets the threshold for cost-effectiveness as the cost of the intervention per disability-adjusted life-year (DALY) averted less than three times the country's annual gross domestic product (GDP) per capita. Highly cost-effective interventions are defined as meeting a threshold per DALY averted of once the annual GDP per capita. We argue that reliance on these thresholds reduces the value of cost-effectiveness analyses and makes such analyses too blunt to be useful for most decision-making in the field of public health. Use of these thresholds has little theoretical justification, skirts the difficult but necessary ranking of the relative values of locally-applicable interventions and omits any consideration of what is truly affordable. The WHO-CHOICE thresholds set such a low bar for cost-effectiveness that very few interventions with evidence of efficacy can be ruled out. The thresholds have little value in assessing the trade-offs that decision-makers must confront. We present alternative approaches for applying cost-effectiveness criteria to choices in the allocation of health-care resources.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2471/blt.14.138206

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
The World Health Report 2002 - Reducing Risks, Promoting Healthy Life
Available, N. A. N. (2003) · Education for Health · doi:10.1080/1357628031000116808 · Cited by 6,078
Methods for the economic evaluation of health care programmes
Wilson, S. (1987) · Journal of Epidemiology & Community Health · doi:10.1136/jech.41.4.355-a · Cited by 4,312
Cost-Benefit Analysis: Concepts and Practice
Boardman, A. E., Greenberg, D. H., Vining, A. R., & Weimer, D. L. (1996) · Cited by 1,920
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., Loder, E., et al. (2013) · BMJ · doi:10.1136/bmj.f1049 · Cited by 1,776
Methods for the economic evaluation of health care programmes, 3rd ed
Adamiak, G. T. (2006) · PubMed Central · Cited by 953
The Value of Life and the Rise in Health Spending
Hall, R. E., & Jones, C. I. (2007) · The Quarterly Journal of Economics · doi:10.1162/qjec.122.1.39 · Cited by 924
Willingness to Pay for a Quality-adjusted Life Year: In Search of a Standard
Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000310 · Cited by 850
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
Thorlund, K., Devereaux, P. J., Wetterslev, J., Guyatt, G. H., Ioannidis, J. P. A., Thabane, L., Gluud, L. L., Als-Nielsen, B. E. T., & Gluud, C. N. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dyn179 · Cited by 834
Cost-effectiveness analysis.
Robinson, R. (1993) · BMJ · doi:10.1136/bmj.307.6907.793 · Cited by 819

Flagged first, then by citations

Show all 42 references

Sorted by citations

Items 701–800 of 853

Cost-utility analysis of lumbar disc herniation: Surgery versus conservative treatment*
Güneş, D., Bostan, S., & Yılmaz, A. (2023) · International Journal of Healthcare Management · doi:10.1080/20479700.2023.2283671 · Cited by 1
The health economics of orthopaedic foot and ankle surgery
Glasser, J., DelliCarpini, G., Walsh, D. F., Chapter-Zylinski, M., & Patel, S. A. (2024) · Foot and Ankle Surgery · doi:10.1016/j.fas.2024.10.004 · Cited by 1
Cost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan
Lee, W.-L., Chou, W., Chang, W.-P., Chang, T.-W., Kuo, C.-N., & Chang, W. (2024) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3536 · Cited by 1
First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
Long, R., & Chen, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-83509-x · Cited by 1
Cost-Benefit and Cost-Effectiveness Analyses
Henderson, L. A. (2025) · doi:10.1093/oso/9780197687420.003.0015 · Cited by 1
Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysis
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331654 · Cited by 1
Prioritizing health system and disease burden factors: an evaluation of the net benefit of transferring health technology interventions to different districts in Zimbabwe
Shamu, S., Rusakaniko, S., & Hongoro, C. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s95037 · Cited by 1
How to Determine the Price of a Service
Kos, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92576-9_36 · Cited by 1
Integrated vaccine economics for countries transitioning from Gavi support
van Wijhe, M., & Simonsen, L. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30461-9 · Cited by 1
Neonatal Screening for Critical Congenital Heart Defects
Ewer, A. K. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-049-7 · Cited by 1
Pricing model for Dengue vaccine in Malaysia
Tay, C. J., Teh, S. Y., & Koh, H. L. (2021) · AIP conference proceedings · doi:10.1063/5.0075361 · Cited by 1
Gesundheitsökonomische Evaluation
Hammerschmidt, T. (2019) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-58314-2_60 · Cited by 1
Cost effectiveness analysis of adopting Gene-Xpert® (GX) for the Diagnosis of Tuberculosis in Egypt
Sedrak, A., Salem, A. A., Amin, T. T., & Amin, W. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.236808 · Cited by 1
Gesundheitsökonomische Evaluation
Hammerschmidt, T. (2018) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-54179-1_60-1 · Cited by 1
Estimating the Avertable Disease Burden and Cost-Effectiveness in Millions Saved Third EditionPreprint
Mirelman, A. J., Glassman, A. L., & Temin, M. (2016) · SSRN Electronic Journal · doi:10.2139/ssrn.2839543 · Cited by 1
Evaluating Structural Interventions
Hensen, B., Dringus, S., Eakle, R., Remme, M., & Hargreaves, J. (2018) · Oxford University Press eBooks · doi:10.1093/oso/9780190675486.003.0012 · Cited by 1
Cost-effectiveness and affordability of anticancer treatment in Brazil
Aguiar, P. N. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.ed96 · Cited by 1
Reply to Author
Rajasingham, R., Enns, E. A., & Vaughn, B. P. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa740 · Cited by 1
Spatial modelling of sand fly vector’s response to a synthetic sex-aggregation pheromone: impact on the incidence of visceral leishmaniasis in rural and urban settingsPreprint
Retkutė, R., Dilger, E., Hamilton, J. G. C., Keeling, M. J., & Courtenay, O. (2020) · medRxiv · doi:10.1101/2020.10.18.20214569 · Cited by 1
Invited Commentary: The Role of Tuberculosis Screening Among Migrants to Low-Incidence Settings in (Not) Achieving Elimination
Campbell, J. R., & Schwartzman, K. (2021) · American Journal of Epidemiology · doi:10.1093/aje/kwab193 · Cited by 1
Cost Effectiveness Analysis of Home-Based Phototherapy Versus Hospital-Based Phototherapy for Treatment of Neonatal Hyperbilirubinemia in shiraz, IranPreprint
Kavosi, Z., Mozafari, M., Rezaee, M., & Keshavarz, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1452573/v1 · Cited by 1
Economic evaluation of home-based counselling to promote exclusive breastfeeding in EgyptPreprint
Mohamed, B. Y., & Kissimova‐Skarbek, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1450911/v1 · Cited by 1
Meta-analysis of economic evaluation studies: Data Harmonisation and Methodological issuesPreprint
Bagepally, B. S., Chaikledkaew, U., Chaiyakunapruk, N., Attia, J., & Thakkinstian, A. (2021) · Research Square · doi:10.21203/rs.3.rs-93779/v2 · Cited by 1
Cost Effectiveness Analysis of CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma in ChinaPreprint
Wu, W., Ding, S., Zhang, M., Zhou, Y., Sun, X., Zhao, Z., Yang, Y., Hu, Y., & Dong, H. (2022) · Research Square · doi:10.21203/rs.3.rs-2177083/v1 · Cited by 1
Public health impact of current and proposed age-expanded perennial malaria chemoprevention: a modelling studyPreprint
Sen, S., Braunack-Mayer, L., Kelly, S. L., Masserey, T., Malinga, J., Moehrle, J. J., & Penny, M. A. (2024) · medRxiv · doi:10.1101/2024.07.31.24311277 · Cited by 1
The Benefits and Costs of Paid Family Leave
Wang, B., Slopen, M. E., Garfinkel, I., Ananat, E., Collyer, S. M., Hartley, R. P., Koutavas, A., & Wimer, C. (2024) · National Bureau of Economic Research · doi:10.3386/w33279 · Cited by 1
PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
Frolov, M. Y., & Rogov, V. A. (2016) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909.2016.9.1.024-032
Trying to Understand World Health Organization's Cost-Effectiveness Threshold
Yang, B. (2015)
Pharmacoeconomic analysis of vemurafenib in treatment of inoperable or metastatic melanoma in patients with BRAF V600 mutation
Колбин, А. С., Kurylev, A. A., Vilyum, I. A., Proskurin, M. A., & Balykina, Y. Е. (2015) · Pharmacoeconomics theory and practice · doi:10.30809/phe.4.2015.4
An Economic evaluation of multi-parasite control strategies in the Philippines
Garcia, F. J. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.106948
Análise de custo-efetividade de obinutuzumabe associado à quimioterapia para o tratamento de pacientes adultos com leucemia linfoide crônica não elegíveis ao tratamento baseado em fludarabina na perspectiva do Sistema Único de Saúde (SUS)
Ho, R. S., Souza, C., Tsuchiya, C. T., Biondo, J. M. L., & Alves, M. R. (2017) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v9.suppl1.41-48
Estudo comparativo entre os custos dos tratamentos clínico, cirúrgico e percutãneo em portadores de doença multiarterial coronária estável: 10 anos de seguimento
Magalhães, C. D. (2017) · doi:10.11606/t.5.2017.tde-18122017-095256
Comentário sobre o artigo “Limiar de custo- -efetividade: uma necessidade para o Brasil?”
Santos, A. L. Q., & Ruas, C. M. (2017) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v9.n2.p237-9
Eficiencia del nimotuzumab en la atención a pacientes con cáncer de cabeza y cuello en Cuba
Ruíz, L. P., Herrera, M. M. C., Escobar, N. I., Fariñas, A. G., & Garay, O. U. (2018) · PharmacoEconomics Spanish Research Articles · doi:10.1007/s40277-018-0078-5
Health Economics: Tools to Measure and Maximize Programme Impact
Kahn, J. G., Mwai, D., Kazi, D. S., & Marseille, E. A. (2019) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-137-54984-6_19
Self-citation
Cardiac CT: Comparative Cost-Effectiveness
Schlett, C. L. (2019) · Contemporary medical imaging · doi:10.1007/978-1-60327-237-7_52
Argentina's Health System's Dilemma: Remain to Being an Old Circus with Elephants and Lions or Wish to Being the Cirque du Soleil [El Dilema del Sistema de Salud de Argentina: Seguir siendo un viejo circo con elefantes y leones o desear ser el Cirque du Soleil]Preprint
Ponce, M. F. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3179556
Economic Spillover Analysis From Public Medical Investments, Using PICO Elements
Farahati, F. (2020) · SAGE Publications Ltd eBooks · doi:10.4135/9781529718171
Impact and cost-effectiveness of nonavalent human papillomavirus vaccination in Switzerland: insights from a dynamic transmission modelPreprint
Riesen, M., Bogaards, J. A., Low, N. N., & Althaus, C. L. (2019) · medRxiv · doi:10.1101/19012674
Pharmacoeconomics of prophylactic, empirical, and diagnostic-based antibiotic treatments: Focus on surgical site infection and hospitalized community-acquired pneumonia
Purba, A. K. R. (2020) · doi:10.33612/diss.128518764
Addressing adverse outcomes following acute illness among children in Sub-Saharan Africa: predicting risks and cost-effectiveness
Brander, R. L. (2019) · ResearchWorks at the University of Washington (University of Washington)
Opt-Out Model of HIV Screening- A Study in Federal Capital Territory Abuja, Nigeria
Ibekwe, E. (2026) · e-space (Manchester Metropolitan University) · doi:10.83056/mmu.32477667
Análise do custo-efetividade da triagem neonatal para a hiperplasia adrenal congênita: comparação de duas populações diagnosticadas com e sem triagem neonatal
de Miranda, M. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-29102020-162042
Cost Effectiveness Analysis Of High-Risk Group Tb Screening In MalaysiaPreprint
Hassan, N. Z. A. M., Razali, A., Shahari, M. R., Kunusagaran, M. S. J. M. N. S., Halili, J., Zaimi, N. A., Bahari, M. S., & Aminuddin, F. (2020) · Research Square · doi:10.21203/rs.3.rs-113831/v1
Cost-Effectiveness of Stroke Unit Compared with Routine Treatment for Stroke Patients in IranPreprint
Gholamhoseini, M. T., Zarein, M., Goodarzi, R. R., Amiresmaili, M., & Mehrpour, M. (2021) · Research Square · doi:10.21203/rs.3.rs-180729/v1
Análise econômica do denosumabe e dos bisfosfonatos no tratamento de pacientes com metástase óssea
Matuoka, J. Y. (2019) · doi:10.11606/t.7.2019.tde-23022021-095026
APOPTOSIS ROLE IN FORMING RADIOIODINE RESISTANCE IN DIFFERENTIATED THYROID CANCER
Альбертович, Г. К., Афанасьева, З. А., & Дамировна, Г. А. (2020) · Avicenna Bulletin · doi:10.25005/2074-0581-2020-22-2-301-310
The Clinical Effectiveness and Cost-Effectiveness of Rituximab Versus Natalizumab in Patients With Relapsing Remitting Multiple SclerosisPreprint
Rezaee, M., Morowvat, M. H., Poursadeghfard, M., Radgoudarzi, A., & Keshavarz, K. (2021) · Research Square · doi:10.21203/rs.3.rs-898078/v1
What have we learned from the economic impact of the Covid-19 outbreak? Critical analysis of economic factors and recommendations for the future.
Franco, J. E. M. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/174883
From sample to sensor
Heidt, B. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20220126bh
The Value of Different Types of Economic and Budget Analysis for Informing Real World Decision Making: the Case of Cervical Cancer Screening in South AfricaPreprint
van Rensburg, C., Meyer‐Rath, G., Campos, N. G., Miot, J., & Lince-Deroche, N. (2020) · Research Square · doi:10.21203/rs.3.rs-62447/v1
Comparing Health Gains, Costs and Cost-Effectiveness of 100s of Interventions in Australia and New Zealand: An Online Interactive League TablePreprint
Carvalho, N., Sousa, T. V., Mizdrak, A., Jones, A. C., Wilson, N., & Blakely, T. A. (2022) · Research Square · doi:10.21203/rs.3.rs-1072911/v1
Cost-Effectiveness Analysis Of Plant Versus Antibiotic Regimens In Treating Patients With Helicobacter Pylori (H. Pylori) Infection In The South Of IranPreprint
Faramarzi, H., Khajoei, Z., Lotfı, F. H., Rezaee, M., Emadi, M., & Keshavarz, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1377344/v1
Decision-Making in the Context of Funding Cancer Therapy
de Graaff, B., & Cox, I. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-84702-9_14
Cost-Effectiveness of Stroke Unit Compared With Routine Treatment For Stroke Patients In IranPreprint
Gholamhoseini, M. T., Goudarzi, R., Zarein, M., Amiresmaili, M., & Mehrpour, M. (2021) · Research Square · doi:10.21203/rs.3.rs-180729/v2
Cost-effectiveness analysis of different methods of treatment of tubal ectopic pregnancy in the south of IranPreprint
Jahromi, B. N., esmaili, E., Fardid, M., Jafari, A., Kavosi, Z., Shiravani, Z., & Keshavarz, K. (2020) · doi:10.21203/rs.3.rs-25488/v1
Cost-effectiveness analysis of initial nonoperative management versus emergency laparoscopic appendectomy for acute complicated appendicitis in JapanPreprint
Sugiura, K., Suzuki, K., Umeyama, T., Omagari, K., Hashimoto, T., & Tamura, A. (2020) · doi:10.21203/rs.3.rs-30317/v1
Health Economics
Teich, N., & Teich, V. (2019) · Springer eBooks · doi:10.1007/978-3-030-16245-0_8
Cost-effectiveness analysis of different methods of treatment of tubal ectopic pregnancy in the south of IranPreprint
Jahromi, B. N., esmaili, E., Fardid, M., Jafari, A., Kavosi, Z., Shiravani, Z., Darab, M. G., & Keshavarz, K. (2020) · doi:10.21203/rs.3.rs-25488/v2
Conceptualizing monetary benchmarks for health investments toward poverty reduction in low- and lower middle-income countries
Chakrabarti, A., & Verguet, S. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000487
[Cost-Utility Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Children and Adolescents in Italy]
Galli, E., Pedone, M. P., Dobreva, M., Bitonti, R., & Turi, R. D. (2022) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v23i1.1527
Interpreting Economic Evaluation in Oral Health
Moodie, M., Tonmukayakul, U., & Gao, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-96289-0_6
One Size Does Not Fit All' : translational health technology assessment in early breast cancer and DCIS
Byng, D. (2022) · doi:10.3990/1.9789036554336
Implementation of mass drug administration of antibiotics in low- and middle- income countriesPreprint
O’Sullivan, N., & McCoy, D. (2022) · Research Square · doi:10.21203/rs.3.rs-2112557/v1
Gesundheitsökonomische Evaluation
Hammerschmidt, T. (2022) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-65219-0_60
Costs and cost-effectiveness of nurse staffing in acute hospital: a systematic reviewPreprint
Griffiths, P., Saville, C. E., Ball, J., Dall’Ora, C., Meredith, P., Turner, L., & Jones, J. (2023) · medRxiv · doi:10.1101/2023.02.03.23285139
Matching-Adjusted Indirect Comparisons Applied for Comparative Efficacy of Haematologic Cancer Drugs within Health Economic Analysis
Muresan, B. (2023) · doi:10.33612/diss.568330158
Different vaccination strategies for preventing coronavirus disease 2019 in Kenya: A dynamic modelling study of health impact and cost-effectiveness
Zhou, D., Shao, H., Tu, Y., Shao, T., Zhao, M., Zhou, K., Wang, K., Tang, X., Xing, Y., Liu, Z., et al. (2023) · Health Decision · doi:10.54844/hd.2022.0295
Zukunftspotenziale der Labormedizin
Schlander, M., Schäfer, R., & Selberg, L. (2023) · Springer eBooks · doi:10.1007/978-3-662-66825-2_5
การประเมนตนทนภาระโรคของผลกระทบทางเดนหายใจจากการเผาตอซงในทโลง ของการผลตขาวในพนภาคเหนอตอนบน
ธรรมพิทักษ์, ก. (2023) · Economics and Business Administration Journal Thaksin University · doi:10.55164/ecbajournal.v15i4.260807
Decision: Mapping out a One Health model of antimicrobial resistance in the context of the Swedish food system: A literature scan — R1/PR6
(2023) · Research Directions One Health · doi:10.1017/one.2023.15.pr6
Recommendation: Mapping out a One Health model of antimicrobial resistance in the context of the Swedish food system: A literature scan — R0/PR4
(2023) · Research Directions One Health · doi:10.1017/one.2023.15.pr4
Author comment: Mapping out a One Health model of antimicrobial resistance in the context of the Swedish food system: A literature scan — R1/PR5
Cousins, M. (2023) · Research Directions One Health · doi:10.1017/one.2023.15.pr5
Review: Mapping out a One Health model of antimicrobial resistance in the context of the Swedish food system: A literature scan — R0/PR3
(2023) · Research Directions One Health · doi:10.1017/one.2023.15.pr3
Review: Mapping out a One Health model of antimicrobial resistance in the context of the Swedish food system: A literature scan — R0/PR2
(2023) · Research Directions One Health · doi:10.1017/one.2023.15.pr2
Author comment: Mapping out a One Health model of antimicrobial resistance in the context of the Swedish food system: A literature scan — R0/PR1
Cousins, M. (2023) · Research Directions One Health · doi:10.1017/one.2023.15.pr1
Preliminary Results of a Healthcare Contingent Valuation Study in Greece*
Afentoula, & Vassilis (2019) · International Journal of Finance Insurance and Risk Management · doi:10.35808/ijfirm/194
Additional file 3 of Cost-effectiveness analysis of Smart Triage, a data-driven pediatric sepsis triage platform in Eastern Uganda
Li, E. C. K., Tagoola, A., Komugisha, C., Nabweteme, A. M., Pillay, Y., Ansermino, J. M., & Khowaja, A. R. (2023) · Figshare · doi:10.6084/m9.figshare.24070316
Additional file 2 of Cost-effectiveness analysis of Smart Triage, a data-driven pediatric sepsis triage platform in Eastern Uganda
Li, E. C. K., Tagoola, A., Komugisha, C., Nabweteme, A. M., Pillay, Y., Ansermino, J. M., & Khowaja, A. R. (2023) · Figshare · doi:10.6084/m9.figshare.24070313
Additional file 1 of Cost-effectiveness analysis of Smart Triage, a data-driven pediatric sepsis triage platform in Eastern Uganda
Li, E. C. K., Tagoola, A., Komugisha, C., Nabweteme, A. M., Pillay, Y., Ansermino, J. M., & Khowaja, A. R. (2023) · Figshare · doi:10.6084/m9.figshare.24070310
Cost-effectiveness of Homocysteine Testing in Screening High-Risk Stroke Patients in China: A Markov Model AnalysisPreprint
Meng, H., Pan, T., Pan, D., Chen, M., Liu, Z., Geng, Y., Ma, X., & Liang, P. (2024) · Research Square · doi:10.21203/rs.3.rs-4471593/v1
Cost-utility analysis of early reconstruction surgery versus conservative treatment for anterior cruciate ligament injury in a lower-middle income country
Deviandri, R., van der Veen, H. C., Purba, A. K. R., Icanervilia, A. V., Lubis, A. M. T., van den Akker‐Scheek, I., & Postma, M. J. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11212-8
Cost-Effectiveness Analysis of Renalof® versus Extracorporeal Shockwave Lithotripsy (ESWL) for the Treatment of Kidney Stones ≤ 1 cm in Nicaragua
Chamorro, M. M. A., Collado, S. A. V., Ruíz, L. P., Soriano, D. M., & García, J. L. (2024) · Health · doi:10.4236/health.2024.167047
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics
Jiang, Y., Hu, W., Hu, B., Gu, H., Cui, Y., & Zhao, X. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2451747
Estimating the unit cost of voluntary medical male circumcision using surgical and device methods in integrated health settings in Kenya
Omondi, R., Kioko, U., Juma, A. W., Serrem, K., Korir, J., Rotich, W., Bitange, D., Bhattacharjee, P., & Moses, S. (2025) · Gates Open Research · doi:10.12688/gatesopenres.15971.1
Health worker delivered Contact and Safety Planning (CASP) for suicide prevention in Chhattisgarh, India: Protocol for a non-randomized, controlled pilot study
Kumar, S., Negi, S., Tripathy, S., Beurs, D. P. D., Pandit, D., Wijnen, B. F. M., Vijayakumar, L., Shields‐Zeeman, L., & Pathare, S. (2025) · F1000Research · doi:10.12688/f1000research.159494.1
Cost-Effectiveness Analysis of Sequential Screening Strategies for Hepatitis B Virus Infection by Birth Cohort — China
Wang, L., Zheng, H., Xia, L., Zhang, G., Wang, F., Yin, Z., & Wang, H. (2025) · China CDC Weekly · doi:10.46234/ccdcw2025.096
Bringing malaria diagnosis and treatment closer to the people: economic rationale for expanding malaria community case management to all ages in a rural district in Madagascar
Ochieng, W., Gutman, J., Dentinger, C., Harimanana, A. N., Irinantenaina, J., Razanadranaivo, H. L., Raobela, O., Mukerabirori, A., Kapesa, L., Garchitorena, A., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05381-y
Integrated Model of Cancer Control for Early Detection and Treatment in Adolescents and Young Adults Living With HIV: Protocol for a Cluster Randomized Controlled Trial
Batabyal, S., Zirali, P., Hoover, S., Mungoni, R., Chelwa, N., Mulenga, D. M., Lusaka, M., Nyblade, L. C., Jones, M., Mwaba, C. K., et al. (2025) · JMIR Research Protocols · doi:10.2196/68254
Multi-Sectoral Integrated Health Screening Program Among Food Service Workers: A Revolutionary Community-Based Approach in Kamrup District, Assam, India
Pallathadka, H., Mishra, D. K., Roy, P. D., Deka, B. C., Saha, J., Kataky, S. S., & Lahkar, M. (2025) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.4.3.1
The Effect of an App‐Based Multimodal Cancer Rehabilitation Programme on Sense of Coherence of Women With Gynaecological Cancer: Study Protocol for a Randomised Controlled Trial
Chow, K. M., Chan, C. W. H., McCarthy, A. L., Zhu, J., Choi, K. C., Siu, K. Y., & Leung, A. W. Y. (2025) · Nursing Open · doi:10.1002/nop2.70260
Safety planning and transdiagnostic cognitive behavioral therapy for adolescent suicide prevention in Mozambique: study protocol for the SPI/TCBT-S hybrid effectiveness/implementation cluster randomized trial
Wagenaar, B. H., Muanido, A., Turner, M., Lovero, K. L., Darnell, D. A., Sharma, M., Comtois, K. A., Ramiro, I., & Cumbe, V. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07102-w
Cost-Effectiveness analysis of insulin therapies for patients with type 2 diabetes in Iran: a long-term analysis using the UKPDS model
Darvishi, A., Daroudi, R., Dehghan, S., Shafiee, G., Ostovar, A., & Heshmat, R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01686-6
“Cost effectiveness analysis and effects of treatment on the years of life with disability among the adult cleft lip and cleft palate patients in Bangladesh”Preprint
Rafique, T., Shams, S. M., & Hasan, M. Z. (2025) · medRxiv · doi:10.1101/2025.08.01.25332786
Evaluating the broad societal value of pembrolizumab in women’s cancer in Brazil
Wijenayake, N., Ladino, D., Patterson, K. W., Rosim, M., Rojas, M., Davies, A., & Young, K. C. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2559532
Diabetes-Attributable Tuberculosis Burden: Global Disparities by Socio-Demographic Index, National Trends in Asia, and Projections (2017–2030)Preprint
Liu, R., Li, R., Zhang, S., Shi, Y., Yang, S., Hou, J., & Li, S. (2025) · Research Square · doi:10.21203/rs.3.rs-7371063/v1
Effective strategies for typhoid conjugate vaccine delivery: Health and economic insights from the 2015 Kampala outbreak
Lee, Y., Salonga, P. K. N., Son, C., Jang, G., Koh, D.-H., Kim, J., & Lee, H. (2025) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0013566 · Cited by 1
Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of EGFR-mutated advanced NSCLC patients
Corso, F., Baili, P., Scotti, F., Mazzeo, L., Torri, V., Russo, G. L., Proto, C., Giani, C., Ganzinelli, M., di Mauro, R. M., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100198
Evidence-based brief cessation advice plus active referral for emergency department patients who smoke: a single-arm, real-world clinical trial
Li, W. H. C., Xia, W., Li, L., Chen, H., Ho, L. L. K., Cheung, K. Y., Xiao, S. H., Chan, Y. C., & Chung, J. O. K. (2025) · BMC Medicine · doi:10.1186/s12916-025-04534-9
Additional file 1 of Meta-analysis of economic evaluation studies: data harmonisation and methodological issues
Bagepally, B. S., Chaikledkaew, U., Chaiyakunapruk, N., Attia, J., & Thakkinstian, A. (2022) · Figshare · doi:10.6084/m9.figshare.19220659

Authors: Marseille, E., Larson, B., Kazi, D. S., Kahn, J. G., & Rosen, S.
Affiliations: Health Strategies International, 555 Fifty-ninth Street, Oakland, California, 94609, United States of America (USA).
Boston University (US)
San Francisco General Hospital (US)
University of California, San Francisco (US)
Corresponding author: Marseille, Elliot
ORCID: Marseille, Elliot
Larson, Bruce
Kazi, Dhruv S
Kahn, James G
Rosen, Sydney
Venue: Bulletin of the World Health Organization
Publisher: WHO Press
Published: 2014-12-15
Volume: 93
Issue: 2
Pages: 118-124
ISSN: 0042-9686 (ISSN-L)
DOI: 10.2471/blt.14.138206
PMC: PMC4339959
OpenAlex: W2133104890
Cited by: 851
References: 42
Citations by year: 2026: 45 · 2025: 68 · 2024: 58 · 2023: 69 · 2022: 93 · 2021: 101 · 2020: 100 · 2019: 105 · 2018: 76 · 2017: 78 · 2016: 40 · 2015: 18
FWCI: 112.73
Type: journal article
Language: en
Open access: diamond
doi.org
Licence: cc-by
Locations: Bulletin of the World Health Organization (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institute of Mental Health (P30MH062246)
National Institute on Drug Abuse (R01DA015612)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
Keywords: cost-effectiveness threshold, WHO-CHOICE, disability-adjusted life years, GDP per capita, healthcare resource allocation, public health decision-making, affordability, cost-effectiveness analysis
MeSH terms: Cost-Benefit Analysis, Developing Countries, Female, Health Priorities, Humans, Pregnancy, Syphilis, Global Health, World Health Organization, HIV Infections, Quality-Adjusted Life Years, Benchmarking, Anti-Retroviral Agents, Insecticide-Treated Bednets, Gross Domestic Product

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Thresholds for the cost–effectiveness of interventions: alternative approaches

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks